## Athena Evidence for B blockers from ACP JC

1. ACP J Club. 2002 Jan-Feb;136(1):7.

<u>Lancet. 2001 May 5;357(9266):1385-90.</u> Carvedilol reduced mortality and morbidity caused by myocardial infarction in patients with left ventricular dysfunction. <u>Jagasia DH</u>, <u>Shivkumar K</u>. University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.

PMID: 11829548 [PubMed]

## Athena Evidence for ACE I from ACP JC

1. ACP J Club. 2003 Sep-Oct;139(2):38Comment on:

N Engl J Med. 2003 Feb 13;348(7):583-92.

ACE inhibitors reduced cardiovascular events and all-cause mortality in elderly persons with hypertension. <u>Davidson R</u>. University of Florida College of Medicine, Gainesville, Florida, USA.

PMID: 12954031 [PubMed]

2. <u>ACP J Club.</u> 2006 Sep-Oct;145(2):35Comment on:

J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S153-5.

Review: ACE inhibitors delay onset of microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic nephropathy. McFarlane PA.

St. Michael's Hospital, Toronto, Ontario, Canada.

PMID: 16944855 [PubMed]

3. ACP J Club. 2005 May-Jun;142(3):65Comment on:

N Engl J Med. 2004 Nov 4;351(19):1941-51.

Trandolapril delayed persistent microalbuminuria in hypertension, type 2 diabetes, and normoalbuminuria. <u>Kudva Y</u>, <u>Hunt D</u>. Mayo Clinic, Rochester, Minnesota, USA.

PMID: 15862064 [PubMed]

4. ACP J Club. 2004 Mar-Apr;140(2):31Comment on:

Lancet. 2003 Sep 6;362(9386):782-8.

Perindopril reduced cardiac events in stable coronary artery disease.

Best PJ, Berger PB.Mayo Clinic, Rochester, Minnesota, USA.

PMID: 15122852 [PubMed]

5. ACP J Club. 2006 Jul-Aug;145(1):19Comment on:

N Engl J Med. 2006 Jan 12;354(2):131-40.

Benazepril was effective and safe for advanced chronic kidney disease without diabetes. Hsu CY. University of California, San Francisco, San Francisco, California, USA.

PMID: 16813367 [PubMed]

6. <u>ACP J Club.</u> 2006 Sep-Oct;145(2):32 Comment on: <u>Arch Intern Med. 2006 Apr</u> 10;166(7):787-96.

Review: ACE inhibitors reduce mortality and cardiovascular endpoints in stable coronary artery disease. Stone PH. Brigham & Women's Hospital, Boston, Massachusetts, USA.

PMID: 16944852 [PubMed]

## Athena Evidence for ARB from ACPJC

1. ACP J Club. 2004 Mar-Apr;140(2):32-3Comment on:

Lancet. 2003 Sep 6;362(9386):759-66.

Lancet. 2003 Sep 6;362(9386):767-71.

Lancet. 2003 Sep 6;362(9386):772-6.

Lancet. 2003 Sep 6;362(9386):777-81.

Candesartan reduced mortality and hospital admissions in chronic heart failure.

Pitt B. University of Michigan, Ann Arbor, Michigan, USA.

PMID: 15122853 [PubMed]

2. 1: <u>ACP J Club.</u> 2002 May-Jun;136(3):82-4.Comment on:

N Engl J Med. 2001 Sep 20;345(12):861-9.

Losartan was renoprotective in diabetic nephropathy independent of its effect on blood pressure. Rabbat CG. McMaster University, Hamilton, Ontario, Canada.

PMID: 11985425 [PubMed]

3. ACP J Club. 2002 May-Jun;136(3):82-4Comment on:

N Engl J Med. 2001 Sep 20;345(12):851-60.

Irbesartan reduced progression of nephropathy caused by type 2 diabetes independent of the effect on blood pressure.

Rabbat CG.McMaster University, Hamilton, Ontario, Canada.

PMID: 11985424 [PubMed]

4. ACP J Club. 2002 May-Jun;136(3):82-4Comment on:

N Engl J Med. 2001 Sep 20;345(12):870-8.

Irbesartan was renoprotective in patients with type 2 diabetes, hypertension, and microalbuminuria.

Rabbat CG. McMaster University, Hamilton, Ontario, Canada.

PMID: 11985423 [PubMed]

5. ACP J Club. 2002 Nov-Dec;137(3):

Lancet. 2002 Mar 23;359(9311):1004-10.

Losartan reduced cardiovascular morbidity and mortality more than atenolol in patients with diabetes and essential hypertension

**Blecker D**, **Blecker SB**.Regional Nephrology Associates and UMDNJ-SOM,

Stratford, New Jersey, USA. PMID: 12418827 [PubMed]

6. <u>ACP J Club.</u> 2002 Nov-Dec;137(3):86Comment on:

Lancet. 2002 Mar 23;359(9311):995-1003.

Losartan reduced strokes and new-onset diabetes more than atenolol in essential hypertension.

Blecker D, Blecker SB. Regional Nephrology Associates and UMDNJ-SOM,

Stratford, New Jersey, USA.

PMID: 12418826 [PubMed

7. ACP J Club. 2005 May-Jun;142(3):60Comment on:

Circulation. 2004 Oct 26;110(17):2618-26.

Candesartan reduced cardiovascular mortality and morbidity in chronic heart failure with low ejection fraction.

Majumdar SR. University of Alberta, Edmonton, Alberta, Canada.

PMID: 15862059 [PubMed]

8. ACP J Club. 2003 Mar-Apr;138(2):37Comment on:

JAMA. 2002 Sep 25;288(12):1491-8.

Losartan was more effective than atenolol for isolated systolic hypertension and left ventricular hypertrophy.

Rembold CM. University of Virginia, Charlottesville, Virginia, USA.

PMID: 12614122 [PubMed

## Athena Evidence for Diuretic from ACP JC

1.ACP J Club. 2005 May-Jun;142(3):64.Comment on:

Am J Cardiol. 2005 Jan 1;95(1):29-35.

Diuretic-based therapy reduced cardiovascular mortality in older patients with isolated systolic hypertension and diabetes.

Alkhenizan A. King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

PMID: 15862063 [PubMed]

2. <u>ACP J Club.</u> 2003 Jul-Aug;139(1):7

ACP J Club. 2003 Nov-Dec;139(3):A15; author reply A15.

Comment on: <u>JAMA. 2002 Dec 18;288(23):2981-97.</u> Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension.

Psaty BM. University of Washington, Seattle, Washington, USA.

PMID: 12841711 [PubMed]

3. ACP J Club. 2004 May-Jun;140(3):72

Lancet. 2003 Nov 8;362(9395):1527-35.

Review: commonly used antihypertensive therapies and targeted blood pressure-lowering regimens reduce cardiovascular events.

McAlister FA. University of Alberta, Edmonton, Alberta, Canada.

PMID: 15122835 [PubMed]

4. ACP J Club. 2004 Jan-Feb;140(1):3Comment on:

JAMA. 2003 May 21;289(19):2534-44.

Review: Low-dose diuretics are the best first-line antihypertensive therapy.

<u>Davidson RA</u>. University of Florida College of Medicine, Gainesville, Florida, USA.

PMID: 14711274 [PubMed]

5. ACP J Club. 2005 Nov-Dec;143(3):63Comment on:

JAMA. 2005 Apr 6;293(13):1595-608.

Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or nonblack patients.

<u>Jain M</u>, <u>Rosenberg M</u>.Providence Portland Medical Center, Portland, Oregon, USA.

PMID: 16262220 [PubMed]

6.